NZ710495A - Therapeutic compositions and methods involving mrna transfection - Google Patents
Therapeutic compositions and methods involving mrna transfectionInfo
- Publication number
- NZ710495A NZ710495A NZ71049514A NZ71049514A NZ710495A NZ 710495 A NZ710495 A NZ 710495A NZ 71049514 A NZ71049514 A NZ 71049514A NZ 71049514 A NZ71049514 A NZ 71049514A NZ 710495 A NZ710495 A NZ 710495A
- Authority
- NZ
- New Zealand
- Prior art keywords
- polypeptide
- mrna
- therapeutic compositions
- methods involving
- cases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751504P | 2013-01-11 | 2013-01-11 | |
| PCT/US2014/011041 WO2014110366A1 (en) | 2013-01-11 | 2014-01-10 | Therapeutic compositions and methods involving mrna transfection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ710495A true NZ710495A (en) | 2019-10-25 |
Family
ID=51167392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ71049514A NZ710495A (en) | 2013-01-11 | 2014-01-10 | Therapeutic compositions and methods involving mrna transfection |
Country Status (13)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2943226B1 (en) * | 2013-01-11 | 2019-03-13 | Herzberg, Mark C. | Therapeutic compositions and methods involving mrna transfection |
| US11253570B2 (en) | 2016-11-07 | 2022-02-22 | Medizinische Hochschule Hannover (Mhh) | S100A8/S100A9-induced immunotolerance in newborn subjects |
| CN107841508A (zh) * | 2017-11-29 | 2018-03-27 | 重庆市中医院 | 含抑铁素重组减毒沙门杆菌及构建方法、表达或递送载体 |
| EP3553525A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Diagnostics of mild or advanced periodontitis |
| EP3553523A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Diagnostics of mild or advanced periodontitis |
| JP6891157B2 (ja) * | 2018-11-15 | 2021-06-18 | 正生 池本 | 機能性ペプチド、それを用いた大腸炎用医薬およびデリバリー剤 |
| CN114561381A (zh) * | 2022-03-14 | 2022-05-31 | 桂林医学院 | 免疫mRNA及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2797402B1 (fr) * | 1999-07-15 | 2004-03-12 | Biomerieux Stelhys | Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune |
| AU7725500A (en) * | 1999-09-30 | 2001-04-30 | National Jewish Medical And Research Center | Method for inhibition of pathogenic microorganisms |
| US7754676B2 (en) * | 2000-09-15 | 2010-07-13 | The United States Of America As Represented By The Department Of Health And Human Services | Defensin-antigen fusion proteins |
| US7338936B2 (en) * | 2000-11-28 | 2008-03-04 | House Ear Institute | Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis |
| DE10121254A1 (de) * | 2001-04-30 | 2002-11-07 | Switch Biotech Ag | MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind |
| WO2004089292A2 (en) * | 2003-04-04 | 2004-10-21 | The Regents Of The University Of California | Immunomodulatory agents for treatment of inflammatory diseases |
| DE10324997A1 (de) * | 2003-06-03 | 2004-12-23 | Switch Biotech Ag | Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden |
| WO2005084180A2 (en) | 2003-12-19 | 2005-09-15 | University Of Cincinnati | Polyamides and polyamide complexes for delivery of oligonucleotide decoys |
| WO2006085987A2 (en) * | 2004-07-09 | 2006-08-17 | University Of Iowa Research Foundation | Rna interference in respiratory epitheial cells |
| WO2006078717A2 (en) * | 2005-01-19 | 2006-07-27 | Beth Israel Deaconess Medical Center | Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis |
| KR100681763B1 (ko) * | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
| US8501478B2 (en) | 2006-06-15 | 2013-08-06 | University Of Cincinnati | Trehalose click polymers for delivery of biologically active molecules |
| EP2167653A2 (en) * | 2007-06-11 | 2010-03-31 | University Of Vermont And State Agricultural College | Treatments involving glutaredoxins and similar agents |
| US8916163B1 (en) * | 2007-12-21 | 2014-12-23 | Vanderbilt University | Method for treating microbial infections |
| DE102010040153A1 (de) * | 2010-09-02 | 2012-03-08 | Robert Bosch Gesellschaft Für Medizinische Forschung Mbh | Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen |
| CA2831613A1 (en) * | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US10174081B2 (en) * | 2011-04-21 | 2019-01-08 | George Mason Research Foundation, Inc. | Antimicrobial peptides and uses therefore |
| EP2943226B1 (en) * | 2013-01-11 | 2019-03-13 | Herzberg, Mark C. | Therapeutic compositions and methods involving mrna transfection |
-
2014
- 2014-01-10 EP EP14738078.6A patent/EP2943226B1/en active Active
- 2014-01-10 PL PL14738078T patent/PL2943226T3/pl unknown
- 2014-01-10 CN CN201480011234.4A patent/CN105473163A/zh active Pending
- 2014-01-10 AU AU2014205298A patent/AU2014205298B2/en active Active
- 2014-01-10 NZ NZ71049514A patent/NZ710495A/en unknown
- 2014-01-10 CA CA2901409A patent/CA2901409C/en active Active
- 2014-01-10 SG SG10201603946PA patent/SG10201603946PA/en unknown
- 2014-01-10 WO PCT/US2014/011041 patent/WO2014110366A1/en not_active Ceased
- 2014-01-10 SG SG11201505431XA patent/SG11201505431XA/en unknown
- 2014-01-10 CA CA3152721A patent/CA3152721C/en active Active
- 2014-01-10 KR KR1020157021685A patent/KR102056511B1/ko active Active
- 2014-01-10 EP EP19155020.1A patent/EP3501551B1/en active Active
- 2014-01-10 ES ES14738078T patent/ES2738315T3/es active Active
- 2014-01-10 JP JP2015552801A patent/JP2016511230A/ja active Pending
- 2014-01-10 US US14/760,077 patent/US20150344537A1/en not_active Abandoned
- 2014-01-10 KR KR1020187006399A patent/KR102119985B1/ko active Active
-
2015
- 2015-07-12 IL IL239898A patent/IL239898B/en active IP Right Grant
-
2016
- 2016-11-08 JP JP2016218023A patent/JP6473729B2/ja active Active
-
2018
- 2018-10-05 JP JP2018190468A patent/JP6956059B2/ja active Active
- 2018-10-10 IL IL262252A patent/IL262252B/en not_active IP Right Cessation
-
2020
- 2020-04-07 US US16/842,489 patent/US11912744B2/en active Active
- 2020-11-09 JP JP2020186487A patent/JP2021019644A/ja not_active Withdrawn
-
2024
- 2024-01-30 US US18/427,711 patent/US12448421B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013342A (es) | Celulas que expresan el receptor de antigeno quimerico (car) con funcion o expresion de tet reducida y metodos de uso de las mismas. | |
| ZA201902247B (en) | Anti¿c1s antibodies and methods of use thereof | |
| EP3248110A4 (en) | Methods and systems for determining proportions of distinct cell subsets | |
| IN2014CN02527A (cg-RX-API-DMAC10.html) | ||
| EA201890926A1 (ru) | ТРИАЗОЛОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ | |
| WO2016065349A8 (en) | Short non-coding protein regulatory rnas (sprrnas) and methods of use | |
| WO2015185875A9 (fr) | Anticorps dirigé contre la galectine 9 et inhibiteur de l'activité suppressive des lymphocytes t régulateurs | |
| PH12017501620A1 (en) | Benzimidazole derivatives as bromodomain inhibitors | |
| HK1248140A1 (zh) | 用於治疗癌症或免疫性疾病的细胞外基质组合物 | |
| GB2496337A (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases | |
| BR112015020290A2 (pt) | métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos | |
| IN2015KN00005A (cg-RX-API-DMAC10.html) | ||
| NZ727701A (en) | Platinum compounds, compositions, and uses thereof | |
| HK1214618A1 (zh) | 含有透明質酸的穩定化組合物 | |
| WO2017044855A3 (en) | Cell penetrating peptides that inhibit irf5 nuclear localization | |
| WO2018226992A8 (en) | Tau aggregation inhibitors | |
| IN2015DN00344A (cg-RX-API-DMAC10.html) | ||
| MX2016010691A (es) | Hidroclorofluoroolefinas e hidrofluoroolefinas estabilizadas. | |
| EP3268022A4 (en) | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same | |
| TW201613974A (en) | Tumor-selective CTLA-4 antagonists | |
| WO2016197024A3 (en) | Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl) | |
| WO2018089901A3 (en) | Exosome delivery system | |
| EA031679B9 (ru) | Производные тетрагидрохинолина в качестве ингибиторов бромодомена | |
| EP3129092A4 (en) | Systems and methods for high concentration nitric oxide delivery | |
| EP3186826A4 (en) | System for measuring levels of radiation reflecting from semiconductor material for use in measuring the dopant content thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 28 JUL 2015; STATUS: REJECTED; KIND CODE: A1 PUBLICATION DATE: 31 JUL 2015; TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 28 JUL 2015; STATUS: REJECTED; KIND CODE: TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 25 JAN 2019; STATUS: PROPOSED; KIND CODE: Effective date: 20190125 |
|
| ERR | Error or correction |
Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 28 JUL 2015; STATUS: REJECTED; KIND CODE: A1 PUBLICATION DATE: 31 JUL 2015; TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 28 JUL 2015; STATUS: REJECTED; KIND CODE: TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 25 JAN 2019; STATUS: REJECTED; KIND CODE: TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 13 MAR 2019; STATUS: PROPOSED; KIND CODE: TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 09 MAR 2019; STATUS: REJECTED; KI Effective date: 20190326 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2022 BY COMPUTER PACKAGES INC Effective date: 20201218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2023 BY COMPUTER PACKAGES INC Effective date: 20211217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2024 BY COMPUTER PACKAGES INC Effective date: 20230117 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2025 BY COMPUTER PACKAGES INC Effective date: 20231230 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2026 BY COMPUTER PACKAGES INC Effective date: 20250117 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2027 BY COMPUTER PACKAGES INC Effective date: 20251217 |